First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

Background Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play a minor role in hemostasis and is, therefore, an attractive anticoagulant drug target. Objectives To evaluate the safety, pharmacokinetic, and pharmacodynamic properties of BAY 2433334, an orally...

Ausführliche Beschreibung